Vir Biotechnology, Inc.
VIR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$10.57
KIRA · Stoqly’s AI analyst, in plain words
- Vir Biotechnology, Inc. had $68.6M of revenue in fiscal 2025, down 7.6% on the year before. Over five years, revenue changed −2.1% a year on average.
- Its operating margin was −699.2%, up 92.1 pts: of every 100 in sales, about −699 is left after running the business.
- Vir Biotechnology, Inc. lost $438M in fiscal 2025.
- Free cash flow was −$397M in fiscal 2025, −578.5% of revenue.
Market cap
$1.8B
P/E
—
Revenue
$68.6M
Net income
−$438M
Free cash flow
−$397M
Operating margin
−699.2%
Vir Biotechnology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−7.6%
No. Sales fell 7.6% last year.
Does it make a profit?
−638.9%
No. It lost money last year.
Does profit turn into cash?
−578.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vir Biotechnology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- Vir Biotechnology, Inc.
- CIK
- 0001706431
Vir Biotechnology, Inc. · VIR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1B | $1.6B | $86.2M | $74.2M | $68.6M |
| Revenue growth | 1,334.4% | 47.5% | −94.7% | −13.9% | −7.6% |
| Gross margin | 94.0% | 90.9% | 96.8% | 98.9% | 100.0% |
| Operating margin | 38.4% | 51.6% | −794.0% | −791.3% | −699.2% |
| Net income | $529M | $516M | −$615M | −$522M | −$438M |
| Net margin | 48.3% | 31.9% | −713.7% | −703.4% | −638.9% |
| Diluted EPS | $3.96 | $3.83 | −$4.59 | −$3.83 | −$3.16 |
| Cash | |||||
| Cash from operations | −$47.6M | $1.7B | −$779M | −$446M | −$392M |
| Capital expenditure | $21.8M | $68.0M | $21.6M | $7.3M | $4.8M |
| Free cash flow | −$69.4M | $1.6B | −$800M | −$454M | −$397M |
| FCF margin | −6.3% | 98.7% | −928.7% | −611.4% | −578.5% |
| Share count change | 12.0% | 1.0% | −0.5% | 1.6% | 1.7% |
| Debt and strength | |||||
| Cash and short-term investments | $565M | $2.4B | $1.5B | $901M | $461M |
| Shareholders' equity | $1.4B | $2.1B | $1.6B | $1.2B | $765M |
| Current ratio | 4.6x | 4.9x | 9.1x | 8.7x | 5.5x |
| Returns and quality | |||||
| Return on equity | 49.2% | 29.4% | −33.5% | −38.1% | −45.7% |
| Return on tangible equity | 38.3% | 25.4% | −39.7% | −46.4% | −59.1% |
| Piotroski F-score | 3 | 5 | 3 | 3 | 3 |
| Altman Z'' | 8.2 | 10.2 | 7.1 | 4.6 | −1.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$8.5M
9 insiders
Of sales under plans
100%
$8.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vir Biotechnology, Inc. · VIR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.57 a share, the company is worth $1.8B.
Source: SEC EDGAR XBRL filings (CIK 0001706431). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.